Gabapentin for the treatment of postherpetic neuralgia: A randomized controlled trial

Michael Rowbotham, Norman Harden, Brett Stacey, Paula Bernstein, Leslie Magnus-Miller

Research output: Contribution to journalArticle

1293 Citations (Scopus)

Abstract

Context. - Postherpetic neuralgia (PHN) is a syndrome of often intractable neuropathic pain following herpes zoster (shingles) that eludes effective treatment in many patients. Objective. - To determine the efficacy and safety of the anticonvulsant drug gabapentin in reducing PHN pain. Design. - Multicenter, randomized, double-blind, placebo-controlled, parallel design, 8-week trial conducted from August 1996 through July 1997. Setting. - Sixteen US outpatient clinical centers. Participants. - A total of 229 subjects were randomized. Intervention. - A 4-week titration period to a maximum dosage of 3600 mg/d of gabapentin or matching placebo. Treatment was maintained for another 4 weeks at the maximum tolerated dose. Concomitant tricyclic antidepressants and/or narcotics were continued if therapy was stabilized prior to study entry and remained constant throughout the study. Main Outcome Measures. - The primary efficacy measure was change in the average daily pain score based on an 11-point Likert scale (0, no pain; 10 worst possible pain) from baseline week to the final week of therapy. Secondary measures included average daily sleep scores, Short-Form McGill Pain Questionnaire (SF-MPQ), Subject Global Impression of Change and investigator-rated Clinical Global Impression of Change, Short Form-36 (SF- 36) Quality of Life Questionnaire, and Profile of Mood States (POMS). Safety measures included the frequency and severity of adverse events. Results. - One hundred thirteen patients received gabapentin, and 89 (78.8%) completed the study; 116 received placebo, and 95 (81.9%) completed the study. By intent-to-treat analysis, subjects receiving gabapentin had a statistically significant reduction in average daily pain score from 6.3 to 4.2 points compared with a change from 6.5 to 6.0 points in subjects randomized to receive placebo (P

Original languageEnglish (US)
Pages (from-to)1837-1842
Number of pages6
JournalJournal of the American Medical Association
Volume280
Issue number21
StatePublished - Dec 2 1998

Fingerprint

Postherpetic Neuralgia
Randomized Controlled Trials
Pain
Placebos
Herpes Zoster
Therapeutics
Safety
Intractable Pain
Maximum Tolerated Dose
Tricyclic Antidepressive Agents
Narcotics
Neuralgia
Pain Measurement
Anticonvulsants
Sleep
Outpatients
Quality of Life
Research Personnel
Outcome Assessment (Health Care)
gabapentin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Rowbotham, M., Harden, N., Stacey, B., Bernstein, P., & Magnus-Miller, L. (1998). Gabapentin for the treatment of postherpetic neuralgia: A randomized controlled trial. Journal of the American Medical Association, 280(21), 1837-1842.

Gabapentin for the treatment of postherpetic neuralgia : A randomized controlled trial. / Rowbotham, Michael; Harden, Norman; Stacey, Brett; Bernstein, Paula; Magnus-Miller, Leslie.

In: Journal of the American Medical Association, Vol. 280, No. 21, 02.12.1998, p. 1837-1842.

Research output: Contribution to journalArticle

Rowbotham, M, Harden, N, Stacey, B, Bernstein, P & Magnus-Miller, L 1998, 'Gabapentin for the treatment of postherpetic neuralgia: A randomized controlled trial', Journal of the American Medical Association, vol. 280, no. 21, pp. 1837-1842.
Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: A randomized controlled trial. Journal of the American Medical Association. 1998 Dec 2;280(21):1837-1842.
Rowbotham, Michael ; Harden, Norman ; Stacey, Brett ; Bernstein, Paula ; Magnus-Miller, Leslie. / Gabapentin for the treatment of postherpetic neuralgia : A randomized controlled trial. In: Journal of the American Medical Association. 1998 ; Vol. 280, No. 21. pp. 1837-1842.
@article{984c9370589e41039d18d2c6b99ca248,
title = "Gabapentin for the treatment of postherpetic neuralgia: A randomized controlled trial",
abstract = "Context. - Postherpetic neuralgia (PHN) is a syndrome of often intractable neuropathic pain following herpes zoster (shingles) that eludes effective treatment in many patients. Objective. - To determine the efficacy and safety of the anticonvulsant drug gabapentin in reducing PHN pain. Design. - Multicenter, randomized, double-blind, placebo-controlled, parallel design, 8-week trial conducted from August 1996 through July 1997. Setting. - Sixteen US outpatient clinical centers. Participants. - A total of 229 subjects were randomized. Intervention. - A 4-week titration period to a maximum dosage of 3600 mg/d of gabapentin or matching placebo. Treatment was maintained for another 4 weeks at the maximum tolerated dose. Concomitant tricyclic antidepressants and/or narcotics were continued if therapy was stabilized prior to study entry and remained constant throughout the study. Main Outcome Measures. - The primary efficacy measure was change in the average daily pain score based on an 11-point Likert scale (0, no pain; 10 worst possible pain) from baseline week to the final week of therapy. Secondary measures included average daily sleep scores, Short-Form McGill Pain Questionnaire (SF-MPQ), Subject Global Impression of Change and investigator-rated Clinical Global Impression of Change, Short Form-36 (SF- 36) Quality of Life Questionnaire, and Profile of Mood States (POMS). Safety measures included the frequency and severity of adverse events. Results. - One hundred thirteen patients received gabapentin, and 89 (78.8{\%}) completed the study; 116 received placebo, and 95 (81.9{\%}) completed the study. By intent-to-treat analysis, subjects receiving gabapentin had a statistically significant reduction in average daily pain score from 6.3 to 4.2 points compared with a change from 6.5 to 6.0 points in subjects randomized to receive placebo (P",
author = "Michael Rowbotham and Norman Harden and Brett Stacey and Paula Bernstein and Leslie Magnus-Miller",
year = "1998",
month = "12",
day = "2",
language = "English (US)",
volume = "280",
pages = "1837--1842",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "21",

}

TY - JOUR

T1 - Gabapentin for the treatment of postherpetic neuralgia

T2 - A randomized controlled trial

AU - Rowbotham, Michael

AU - Harden, Norman

AU - Stacey, Brett

AU - Bernstein, Paula

AU - Magnus-Miller, Leslie

PY - 1998/12/2

Y1 - 1998/12/2

N2 - Context. - Postherpetic neuralgia (PHN) is a syndrome of often intractable neuropathic pain following herpes zoster (shingles) that eludes effective treatment in many patients. Objective. - To determine the efficacy and safety of the anticonvulsant drug gabapentin in reducing PHN pain. Design. - Multicenter, randomized, double-blind, placebo-controlled, parallel design, 8-week trial conducted from August 1996 through July 1997. Setting. - Sixteen US outpatient clinical centers. Participants. - A total of 229 subjects were randomized. Intervention. - A 4-week titration period to a maximum dosage of 3600 mg/d of gabapentin or matching placebo. Treatment was maintained for another 4 weeks at the maximum tolerated dose. Concomitant tricyclic antidepressants and/or narcotics were continued if therapy was stabilized prior to study entry and remained constant throughout the study. Main Outcome Measures. - The primary efficacy measure was change in the average daily pain score based on an 11-point Likert scale (0, no pain; 10 worst possible pain) from baseline week to the final week of therapy. Secondary measures included average daily sleep scores, Short-Form McGill Pain Questionnaire (SF-MPQ), Subject Global Impression of Change and investigator-rated Clinical Global Impression of Change, Short Form-36 (SF- 36) Quality of Life Questionnaire, and Profile of Mood States (POMS). Safety measures included the frequency and severity of adverse events. Results. - One hundred thirteen patients received gabapentin, and 89 (78.8%) completed the study; 116 received placebo, and 95 (81.9%) completed the study. By intent-to-treat analysis, subjects receiving gabapentin had a statistically significant reduction in average daily pain score from 6.3 to 4.2 points compared with a change from 6.5 to 6.0 points in subjects randomized to receive placebo (P

AB - Context. - Postherpetic neuralgia (PHN) is a syndrome of often intractable neuropathic pain following herpes zoster (shingles) that eludes effective treatment in many patients. Objective. - To determine the efficacy and safety of the anticonvulsant drug gabapentin in reducing PHN pain. Design. - Multicenter, randomized, double-blind, placebo-controlled, parallel design, 8-week trial conducted from August 1996 through July 1997. Setting. - Sixteen US outpatient clinical centers. Participants. - A total of 229 subjects were randomized. Intervention. - A 4-week titration period to a maximum dosage of 3600 mg/d of gabapentin or matching placebo. Treatment was maintained for another 4 weeks at the maximum tolerated dose. Concomitant tricyclic antidepressants and/or narcotics were continued if therapy was stabilized prior to study entry and remained constant throughout the study. Main Outcome Measures. - The primary efficacy measure was change in the average daily pain score based on an 11-point Likert scale (0, no pain; 10 worst possible pain) from baseline week to the final week of therapy. Secondary measures included average daily sleep scores, Short-Form McGill Pain Questionnaire (SF-MPQ), Subject Global Impression of Change and investigator-rated Clinical Global Impression of Change, Short Form-36 (SF- 36) Quality of Life Questionnaire, and Profile of Mood States (POMS). Safety measures included the frequency and severity of adverse events. Results. - One hundred thirteen patients received gabapentin, and 89 (78.8%) completed the study; 116 received placebo, and 95 (81.9%) completed the study. By intent-to-treat analysis, subjects receiving gabapentin had a statistically significant reduction in average daily pain score from 6.3 to 4.2 points compared with a change from 6.5 to 6.0 points in subjects randomized to receive placebo (P

UR - http://www.scopus.com/inward/record.url?scp=0032477305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032477305&partnerID=8YFLogxK

M3 - Article

C2 - 9846778

AN - SCOPUS:0032477305

VL - 280

SP - 1837

EP - 1842

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 21

ER -